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61 
ABSTRACT 62 
Introduction: RANKL stimulates NF-kB-dependent cell-signalling and acts as the primary signal 63 
for bone resorption. Retrospective analysis of a large trial comparing denosumab versus zoledronic 64 
acid in bone metastatic solid tumours suggested significant overall survival (OS) advantage for 65 
lung cancer patients with denosumab. The randomised open-label phase III SPLENDOUR trial 66 
was designed to evaluate whether the addition of denosumab to standard first-line platinum-based 67 
doublet chemotherapy improves OS in advanced NSCLC. 68 
Methods: Stage IV NSCLC patients were randomised 1:1 to either chemotherapy with or without 69 
denosumab (120mg every 3-4 weeks), stratified by presence of bone metastases (at diagnosis), 70 
ECOG performance status, histology and region. To detect an OS increase from 9-11.25 months 71 
(HR=0.80), 847 OS events were required. The trial closed prematurely due to decreasing accrual 72 
rate. 73 
Results: 514 patients were randomised, 509 receiving ≥1 dose of assigned treatment 74 
(chemotherapy:252, chemotherapy-denosumab:257). Median age was 66.1 years, 71% male, 59% 75 
former smokers. Bone metastases were identified in 275(53%) patients. Median OS(95%CI) was 76 
8.7(7.6-11.0) in the control versus 8.2(7.5-10.4) months in the chemotherapy-denosumab-arm, 77 
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(HR=0.96;95%CI:[0.78-1.19]; 1-sided P=0.36). For patients with bone metastasis 78 
HR=1.02(95%CI:[0.77-1.35]), while for those without HR=0.90(95%CI:[0.66-1.23]). Grade≥3 79 
adverse events were observed in 40.9%/5.2%/8.7% versus 45.5%/10.9%/10.5% of patients. 80 
Conditional power for OS benefit was ≤10%. 81 
Conclusions: Denosumab was well tolerated without unexpected safety concerns. There was no 82 
OS improvement for denosumab when added to chemotherapy in the ITT, and in the subgroups 83 
with and without bone metastases. Our data do not provide evidence of a clinical benefit for 84 
denosumab in NSCLC patients without bone metastases. 85 
86 
KEYWORDS: 87 
NSCLC, RANK, RANKL, Denosumab, bone metastases 88 
89 
INTRODUCTION 90 
Lung cancer is the leading cause of cancer mortality and histologically non-small cell lung cancer 91 
(NSCLC) accounts for 85% of lung cancers. Life expectancy of individuals with lung cancer has 92 
increased with better treatments, including targeted therapies and immunotherapy.  93 
Bone metastases are a significant cause of morbidity in advanced cancer and 30–45% of patients 94 
with advanced NSCLC will develop bone metastases during the course of their disease, with a post 95 
mortem documentation in 36%. Retrospective data demonstrate that in two thirds of patients with 96 
bone metastatic disease had bone metastases already at the time of initial diagnosis.1-497 
Patients with metastatic bone disease may suffer from skeletal-related events (SREs), such as 98 
fractures, pain requiring radiation or bone surgery, spinal cord compression, severely affecting 99 
quality of life. Lung cancer patients are known to present with high frequency of SREs5,6 while 100 
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the occurrence of NSCLC-associated SREs was shown to predict an unexpectedly short life 101 
expectancy with virtually no long-term survivors.4102 
Signalling through binding of the Receptor activator of NF-kB ligand (RANK) to its ligand 103 
RANKL, was first discovered as a means of communication between T-cells and dendritic cells. 104 
RANKL activates osteoclasts for bone resorption, and enables mammary gland and secondary 105 
lymph node organogenesis7. RANKL has also profound immune modulating effects since the 106 
binding to its receptor induces T-reg cells and chemo-resistance through the activation of multiple 107 
signal transduction pathways.8,9 As a consequence, RANKL-inhibition enhances immune 108 
responses and holds promise as immune-therapeutic agent to treat cancer. RANK- and RANKL-109 
expressions have been observed in some tumour types with early clinical data, suggesting a 110 
potential anti-tumour effect of RANK-pathway inhibitors.8111 
The RANKL inhibitor denosumab, a fully human monoclonal IgG2 antibody, is approved for the 112 
prevention of skeletal-related events in patients with advanced malignancies involving bone, 113 
including solid tumours and multiple myeloma. 114 
In a pivotal phase III trial of denosumab versus zoledronic acid for the treatment of bone 115 
metastases in advanced cancer, denosumab significantly delayed first on-study SREs in NSCLC.10116 
In a post-hoc, exploratory analysis of 811 lung cancer patients, denosumab was associated with 117 
improved overall survival (OS) versus zoledronic acid. Specifically, in NSCLC, a HR of 0.79 (9.5 118 
versus 8.1 months, 95%CI:[0.65-0.95]) was described.11119 
The SPLENDOUR trial was designed to address in a randomised manner whether the addition of 120 
denosumab to standard first-line platinum-based doublet chemotherapy improves OS in advanced 121 
NSCLC. 122 
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MATERIAL AND METHODS 123 
Design 124 
SPLENDOUR (ETOP 5-12 /EORTC 08111), an international, multi-centre, randomised, open-125 
label phase III trial, evaluated the addition of denosumab to standard first-line anticancer treatment 126 
in advanced NSCLC. Safety was monitored by the ETOP Independent Data Monitoring 127 
Committee (IDMC). The trial is registered with ClinicalTrials.gov, number NCT02129699. 128 
Patients 129 
Patients were recruited from 55 centres in Austria, Belgium, France, Germany, Ireland, Italy, 130 
Slovenia, Spain, Switzerland and the United Kingdom. 131 
Eligible patients were ≥18 years, had measurable or evaluable stage IV NSCLC, (with or without 132 
bone metastases), Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–2, 133 
available tumour tissue for translational research, life expectancy of at least 3 months, and 134 
adequate renal, hepatic and haematological functions. Patients with documented sensitising EGFR 135 
activating mutation or ALK rearrangements, symptomatic brain metastases, prior chemotherapy 136 
or targeted therapy for metastatic disease, or severe, uncorrected hypocalcaemia or hypercalcaemia 137 
were excluded. Screening for EGFR/ALK was optional, following local standards, but strongly 138 
encouraged in non-squamous histology, while CT scan or MRI of brain was not mandatory and 139 
only recommended in case of clinically suspected brain metastasis. Following a protocol 140 
amendment, activated when the majority of patients had already been randomised, one line of prior 141 
therapy with an immune checkpoint inhibitor was allowed. 142 
Study treatment and assessments 143 
Patients were randomised 1:1 to receive either four to six cycles of platinum-based doublet 144 
chemotherapy (platinum compound plus gemcitabine or pemetrexed for non-squamous cell 145 
histology) or platinum-based doublet chemotherapy plus denosumab at a dose of 120 mg, 146 
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subcutaneously every three to four weeks (chemotherapy-denosumab-arm). Denosumab was 147 
continued beyond disease progression and given concomitantly with subsequent treatment lines, 148 
for as long as it was tolerated. Zoledronic acid administration was only allowed in the 149 
chemotherapy-arm when there were skeletal metastases at baseline, as this is a standard of care. 150 
Pemetrexed or erlotinib maintenance treatment after doublet chemotherapy was allowed in both 151 
arms. 152 
CT-scans for tumour response assessments were performed at baseline, chemotherapy cycle 3 and 153 
then every 12 weeks until progression. All patients underwent a PET-CT or bone scan at baseline 154 
for specific bone metastases status assignment. Bone imaging (including bone scan) during 155 
treatment and at progression were also performed if clinically indicated, i.e., in case of suspected 156 
bone metastases. In the event of equivocal results, further confirmation using bone MRI, CT, X-157 
Ray or biopsy was recommended. 158 
Adverse events were reported following the Common Terminology Criteria for Adverse Events 159 
version 4.0 (CTCAE v4.0).  160 
Statistical plan 161 
SPLENDOUR used a centralised random assignment of patients using the block design technique, 162 
stratified by bone metastases (presence versus absence), ECOG PS (0/1 versus 2), histology 163 
(squamous versus other), and geographic region (Eastern versus Western versus Southern Europe) 164 
to balance pemetrexed availability, maintenance strategy and standard of care. 165 
The primary endpoint was OS. Secondary endpoints included progression-free survival (PFS), 166 
response by RECIST v1.1, and safety. OS and PFS, estimated from time of randomisation, were 167 
conducted on the intention-to-treat (ITT) population and analysed using Cox regression. 168 
Comparisons between treatment arms were made by score test adjusted for stratification factors. 169 
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Sensitivity analysis was performed based on log-rank test and Kaplan-Meier estimates and plots 170 
were produced.  171 
For PFS analysis, an event was defined as disease progression or death, whichever occurred first. 172 
Alive patients without progression were censored at date of last follow-up.  173 
Using 90% power and one-sided type I error of 2.5%, demonstration of an increase in median OS 174 
to 11.25 months in the chemotherapy-denosumab-arm relative to 9 months in the chemotherapy-175 
arm (equivalent to HR=0.80) required observation of 847 deaths. Assuming an accrual rate of 176 
15 patients/month in the first 6 months and 30 patients/month thereafter, 1000 patients were 177 
required to be recruited over a period of 37 months and followed for an additional 14 months after 178 
the randomisation of the last patient, to reach the required number of events. The trial was designed 179 
with a futility interim analysis (IA) at 30% of the information time. 180 
Subgroup analyses for the treatment effect on OS and PFS by bone metastasis status at 181 
randomisation, ECOG PS and histology were predefined. The accrual in the bone metastases 182 
stratum was expected to be 30%. The same OS improvement was assumed for both bone 183 
metastases strata in the chemotherapy-denosumab-arm. 184 
The planned IA for futility was conducted when 274 events (32.4% of information) for the primary 185 
endpoint were available. Results were presented to the IDMC in September 2017, which 186 
recommended continuation of the study as per protocol. However, the Steering Committee closed 187 
recruitment as of January 2018, considering that completion of accrual was not feasible in the 188 
context of recent immunotherapy advances and the multiplicity of immunotherapy-based ongoing 189 
clinical trials in this specific clinical scenario. In fact, subsequent survival improvement and 190 
regulatory approval of combined anti-PD(L)-1 and immunotherapy and chemotherapy would have 191 
ethically and practically prevented the continuation of this trial. 192 
193 
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RESULTS 194 
Patients and Treatment 195 
Between 11/12/2014 and 10/01/2018, 514 patients were randomised from 55 institutions. The 196 
patient flow is summarized in the Consort Diagram in Figure 1. The analysis includes data 197 
available as of 25 January 2018.  198 
From the 514 randomised patients, 509 started treatment (252 chemotherapy; 257 chemotherapy-199 
denosumab). Thirty-three patients were retrospectively considered ineligible (17 chemotherapy, 200 
16 chemotherapy-denosumab). The primary endpoint analysis was performed on the ITT 201 
population of all 514 randomised patients. Safety analysis was based on the 509 patients who 202 
started treatment. Of note, three patients randomised to chemotherapy, had actually received 203 
denosumab.  204 
Baseline characteristics were well balanced between the two treatment arms (Table 1). The 205 
majority of patients had non-squamous histology (72% overall; 73% chemotherapy and 71% 206 
chemotherapy-denosumab), ECOG PS of 0/1 (89%; 90% chemotherapy, 89% chemotherapy-207 
denosumab, were from Western Europe (61%; 60% chemotherapy, 63% chemotherapy-208 
denosumab) and had a median age of 66.1 years (65.4 chemotherapy, 66.5 chemotherapy-209 
denosumab). Bone metastases at baseline were observed in 54% of patients (54% chemotherapy, 210 
53% chemotherapy-denosumab). Zoledronic acid was administered in 70 (27.5%) of the 211 
chemotherapy patients. 212 
Median duration (range) of trial treatment was 12.4 weeks (3.0-24.9) in the chemotherapy-arm and 213 
21.4 weeks (3.0-148.6) in the chemotherapy-denosumab-arm. Median duration of doublet 214 
chemotherapy was similar between the two arms (11.9 versus 12.0 weeks for cisplatin, 12.0 versus 215 
12.0 weeks for carboplatin, 12.4 versus 12.0 weeks for gemcitabine and 12.0 versus 12.0 weeks 216 
for pemetrexed) for chemotherapy-arm versus chemotherapy-denosumab-arm, respectively. 217 
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Median duration for denosumab treatment was 21.4 weeks (range: 3.0-147.7), with a median 218 
cycles number of six. At the time of analysis, eight (3.2%) patients in the chemotherapy-arm and 219 
36 (14%) in the chemotherapy-denosumab-arm were still on treatment (reasons for treatment 220 
discontinuation in Table S1). 221 
Efficacy analysis 222 
At the cut-off date for the final analysis (25/01/2018), 159 patients (chemotherapy-arm: 77; 223 
chemotherapy-denosumab-arm: 88) were still on follow-up, with median follow-up of 19.8 months 224 
(95%CI:[16.8-25.3]) for 25.3 months (95%CI:[19.7-29.0]) for the chemotherapy-arm and 225 
chemotherapy-denosumab-arm, respectively. 226 
On the ITT cohort of 514 randomised patients, 355 deaths were observed. Median OS was 8.7 227 
months in the chemotherapy-arm and 8.2 in the chemotherapy-denosumab-arm, corresponding to 228 
HR=0.96 (95%CI:[0.78-1.19]; stratified 1-sided P-value=0.36) (Figure 2A), confirmed by 229 
sensitivity analysis (log-rank P=0.34).  230 
Based on these results, the null hypothesis H0 cannot be rejected and thus OS chemotherapy-231 
denosumab-arm was not found to be significantly superior to the chemotherapy-arm. Conditional 232 
power calculations indicated that, even if recruitment had been completed, the power of detecting 233 
a significant OS benefit would be less than 10%. 234 
Similarly, PFS did not display a significant difference between the two treatment arms (Figure 235 
2B). The same number of 228 PFS events, were observed in both arms (chemotherapy: 192 236 
progressions and 36 deaths without progression; chemotherapy-denosumab: 186 and 42), with 237 
almost identical median PFS (chemotherapy: 4.7 months, 95%CI:[4.1-5.2]; chemotherapy-238 
denosumab: 4.7 months, 95%CI:[4.2-5.3]; stratified Cox 1-sided P=0.46). 239 
One complete response was observed in each treatment arm, while objective response rate (ORR) 240 
was 29.4% on chemotherapy-arm and 30.5% on chemotherapy-denosumab-arm (Fisher’s exact P-241 
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value=0.85). Stable disease occurred in 39.6% on chemotherapy and 33.6% on chemotherapy-242 
denosumab, respectively (Table 2).  243 
Subgroup analyses on the primary endpoint OS are presented in Figure 3 (unadjusted Cox 244 
analysis). No significant treatment effect was found in any of the subgroups examined, including 245 
for presence or absence of bone metastases at randomization. Hazard ratios for patients with and 246 
without bone metastases at randomization were 1.02 (95% CI: [0.77-1.35]) and 0.90 (95% CI: 247 
[0.66-1.23]), respectively (interaction P=0.55). Of note, the interaction of treatment with ECOG 248 
performance status was found significant (P=0.027) (Figure 3). Analogous stratified subgroup 249 
results for both OS and PFS are summarized in Table S2.  250 
Bone events were recorded in 48 patients (9.3%) overall, 7.7% and 11% on chemotherapy and 251 
chemotherapy-denosumab respectively (Fisher’s exact P-value=0.13, Table S3). 252 
Safety analysis 253 
The number of patients with grade 3/4/5 AEs were 103(40.9%)/13(5.2%)/22(8.7%) on 254 
chemotherapy versus 117(45.5%)/28(10.9%)/27(10.5%) on chemotherapy-denosumab, 255 
respectively. The most common grade≥3 AEs on chemotherapy were hypertension in 20(7.9%) of 256 
the patients (2 grade4), lung infection in 19(7.5%) patients (3 grade5), dyspnoea and fatigue each 257 
in 13(5.2%) patients, and sepsis in 10(4%) patients (7 grade5; 3 grade4). Similarly, on 258 
chemotherapy-denosumab, hypertension was the most frequent AE (40 patients; 15.6%; 3 grade4). 259 
Lung infection is recorded for 28(10.9%) patients (2 grade4; 3 grade5). Other common AES on 260 
chemotherapy-denosumab included fatigue in 31(12.1%) patients, dyspnoea in 21(8.2%; 1 261 
grade4), nausea in 17(6.6%) and febrile neutropenia in 13(5.1%, 4 grade4; 2 grade5). Sepsis was 262 
reported for 11(4.3%) patients (7 grade4, 4 grade5). The full table of grade≥3 AEs by treatment 263 
arm as well as lab toxicities are available in supplement Tables S4 and S5. 264 
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Twenty-two (8.7%) patients on chemotherapy had serious AEs (SAEs) with a fatal outcome (nine 265 
of which were toxic deaths); while on chemotherapy-denosumab, 32 (12.4%) had a SAE of fatal 266 
outcome and nine toxic deaths were observed. 267 
268 
DISCUSSION 269 
While a link between RANKL-signalling and breast cancer bone and systemic progression has 270 
been established,12-14 much less is known about RANKL-signalling in primary tumours from other 271 
carcinomas such as lung cancer. 272 
NF-kB-signalling in tumour epithelial cells played an important role in the development of lung 273 
tumours in NSCLC mouse models15-20 and RANKL could theoretically participate in the 274 
elaboration of an NF-kB response in lung tumour cells.21 Of particular interest and supporting the 275 
design of this trial was the finding that RANKL blocking agents can impair the growth of primary 276 
tumours in several mouse models of lung adenocarcinoma with a predominant effect observed in 277 
the presence of KRAS mutation.22278 
SPLENDOUR was designed to evaluate whether denosumab, given in addition to standard first-279 
line platinum-based doublet chemotherapy and continued across subsequent lines of treatments, 280 
improves OS in advanced NSCLC. Denosumab in addition to standard chemotherapy was well 281 
tolerated without major safety concerns. However, the final analysis of SPLENDOUR did not 282 
show an improvement in OS for the addition of denosumab compared to chemotherapy. Subset 283 
analyses did not show survival differences between patient cohorts with and without bone 284 
metastases and irrespective of histological subtypes. 285 
Our results align with the data from a company sponsored randomised phase II biomarker-driven 286 
trial of denosumab versus placebo in NSCLC (NCT01951586), which recruited a similar group of 287 
226 patients in parallel to SPLENDOUR. The reported OS was better at 10.9 months for placebo 288 
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and 10.7 months for denosumab, respectively (HR=1.06, 95%CI:[0.75-1.59]) than in 289 
SPLENDOUR (median OS around 8 months). There was no correlation between OS and RANK-290 
expression on tissue (data obtained from clinicaltrials.gov). 291 
The SPLENDOUR trial planned to randomise 1000 patients. However, the recruitment stopped 292 
prematurely in January 2018 after the randomisation of 514 patients, due to slow accrual. 293 
Recruitment, initially very fast, was negatively impacted by a rapidly changing treatment 294 
landscape, especially with the advent of frontline immunotherapy becoming available in 295 
competitive clinical trials and subsequently as standard of care.  296 
While chemotherapy, concomitantly or not with immunotherapy, will most probably remain a key 297 
component of lung cancer treatment, SPLENDOUR was unable to demonstrate any improvement 298 
of its activity by adding denosumab. An overall survival of less than one year is in keeping with 299 
the historical results pre-targeted and pre-immunotherapy, in a trial with unselected NSCLC 300 
patients, notably including PS2 patients.23 Serum and tumour samples were collected from patients 301 
and translational analyses are ongoing, aiming at identifying a subset of patients who might benefit 302 
from the addition of denosumab. 303 
Conclusion 304 
In conclusion, denosumab in combination with doublet chemotherapy in patients with stage IV 305 
NSCLC did not improve OS, ORR or PFS overall or in any subgroup analysed. There were no 306 
new safety concerns. 307 
308 
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